Hereditary angioedema (HAE) is a rare, debilitating condition causing unpredictable, painful swelling attacks. With recent approvals like DAWNZERA™ (donidalorsen) in the EU (January 2026) and expanded pediatric options for existing drugs, the focus now shifts to the pipeline of innovative prophylactics. These aim to reduce attack frequency with less frequent dosing, oral convenience, or even one-time treatments.
Several Phase 3 trials are advancing, promising to reshape HAE management:
- ALPHA-ORBIT for navenibart (STAR-0215, now under BioCryst after Astria acquisition): This monoclonal antibody targets plasma kallikrein for long-acting prevention (every 3 or 6 months via subcutaneous injection).
- CHAPTER-3 for deucrictibant (Pharvaris): An oral bradykinin B2 receptor antagonist extended-release tablet dosed once daily for prophylaxis in adults and adolescents 12+.
- STOP-HAE for ADX-324 (ADARx Pharmaceuticals): A long-acting siRNA targeting prekallikrein mRNA, administered subcutaneously every 3-6 months for consistent attack prevention.
Looking further ahead, lonvoguran ziclumeran (lonvo-z, NTLA-2002 from Intellia Therapeutics) stands out as potentially transformative - a one-time CRISPR-based gene editing therapy that inactivates the KLKB1 gene to durably lower kallikrein levels. There is a potential U.S. launch in 2027, offering hope for a functional "cure" that eliminates the need for ongoing prophylaxis.
These developments highlight a shift toward more patient-friendly options: fewer injections, oral alternatives, and durable gene-based solutions.
Stay tuned to sources like HAEi.org, ClinicalTrials.gov, and company updates for the latest trial readouts and regulatory news. The future of HAE treatment looks promising.
Treatments for Hereditary Angioedema (HAE) (click to enlarge the image).